Advanced search
Publication Cover
Cancer Management and Research Volume 11, 2019 - Issue
Submit an article Journal homepage
110
Views
12
CrossRef citations to date
0
Altmetric
Review

Evaluating vandetanib in the treatment of medullary thyroid cancer: patient-reported outcomes

Poupak Fallahi1 Department of Translational Research and of New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy
,
Silvia Martina Ferrari2 Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
,
Giusy Elia2 Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
,
Francesca Ragusa2 Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
,
Sabrina Rosaria Paparo2 Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
,
Ilaria Ruffilli2 Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
,
Armando Patrizio2 Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
,
Gabriele Materazzi3 Department of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, Pisa, Italy
&
Alessandro Antonelli2 Department of Clinical and Experimental Medicine, University of Pisa, Pisa, ItalyCorrespondence[email protected]
 show all
Pages 7893-7907 | Published online: 21 Aug 2019

Citations (12)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Asma Almansoori, Poorna Manasa Bhamidimarri, Riyad Bendardaf & Rifat Hamoudi. (2022) In silico Analysis of Publicly Available Transcriptomics Data Identifies Putative Prognostic and Therapeutic Molecular Targets for Papillary Thyroid Carcinoma. International Journal of General Medicine 15, pages 3097-3120.
Read now

Articles from other publishers (11)

Ravi Kumar Bandaru, Lopamudra Giri, Gamidi Rama Krishna & Rambabu Dandela. (2024) Novel molecular adducts of an anti-cancer drug vandetanib with enhanced solubility. CrystEngComm 26:3, pages 248-260.
Crossref
Jacqueline Wen Hui Leow, Yuxiang Gu & Eric Chun Yong Chan. (2023) Investigating the relevance of CYP2J2 inhibition for drugs known to cause intermediate to high risk torsades de pointes. European Journal of Pharmaceutical Sciences 187, pages 106475.
Crossref
Carla Colombo, Simone De Leo, Matteo Trevisan, Noemi Giancola, Anna Scaltrito & Laura Fugazzola. (2022) Daily Management of Patients on Multikinase Inhibitors’ Treatment. Frontiers in Oncology 12.
Crossref
Francesca Ragusa, Silvia Martina Ferrari, Giusy Elia, Sabrina Rosaria Paparo, Eugenia Balestri, Chiara Botrini, Armando Patrizio, Valeria Mazzi, Giovanni Guglielmi, Rudy Foddis, Claudio Spinelli, Salvatore Ulisse, Alessandro Antonelli & Poupak Fallahi. (2022) Combination Strategies Involving Immune Checkpoint Inhibitors and Tyrosine Kinase or BRAF Inhibitors in Aggressive Thyroid Cancer. International Journal of Molecular Sciences 23:10, pages 5731.
Crossref
Poupak Fallahi, Silvia Martina Ferrari, Maria Rosaria Galdiero, Gilda Varricchi, Giusy Elia, Francesca Ragusa, Sabrina Rosaria Paparo, Salvatore Benvenga & Alessandro Antonelli. (2022) Molecular targets of tyrosine kinase inhibitors in thyroid cancer. Seminars in Cancer Biology 79, pages 180-196.
Crossref
Tobiloba C. Elebiyo, Damilare Rotimi, Ikponmwosa O. Evbuomwan, Rotdelmwa Filibus Maimako, Matthew Iyobhebhe, Oluwafemi Adeleke Ojo, Olarewaju M. Oluba & Oluyomi S. Adeyemi. (2022) Reassessing vascular endothelial growth factor (VEGF) in anti-angiogenic cancer therapy. Cancer Treatment and Research Communications 32, pages 100620.
Crossref
Aurora De Leo, Emanuele Di Simone, Alessandro Spano, Giulia Puliani & Fabrizio Petrone. (2021) Nursing Management and Adverse Events in Thyroid Cancer Treatments with Tyrosine Kinase Inhibitors. A Narrative Review. Cancers 13:23, pages 5961.
Crossref
Bin Li, Yi Kuang, Yang Yi, Xue Qiao, Lei Liang & Min Ye. (2021) Chemical modifications of ergostane-type triterpenoids from Antrodia camphorata and their cytotoxic activities. Bioorganic & Medicinal Chemistry Letters 43, pages 128066.
Crossref
Rosa M. García-Moreno, Óscar Moreno-Domínguez, Beatriz Castelo-Fernández, Laura Yébenes-Gregorio, Isabel Torres-Sánchez & Cristina Álvarez-Escolá. (2021) An Unusual Case of Hypopituitarism as an Adverse Effect of Vandetanib and Remission of Breast Metastases in a Patient with Medullary Thyroid Cancer. Oncology Research and Treatment 44:10, pages 568-572.
Crossref
Yusuf Ilhan, Hasan Senol Coskun, Unal Atas & Sema Sezgin Goksu. (2020) Polycythemia after vandetanib treatment in metastatic medullary thyroid carcinoma: A rare case report. Current Problems in Cancer: Case Reports 1, pages 100011.
Crossref
Shinya Kitamura, Takuya Maeda & Teruki Yanagi. (2020) Vandetanib inhibits cell growth in EGFR-expressing cutaneous squamous cell carcinoma. Biochemical and Biophysical Research Communications 531:3, pages 396-401.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.